COVID-19 vaccine: recent advancements and future prospects

Abstract

Nowadays, although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic has been handled with long-term management globally, the virus strains keep continuous evolution in an uncertain direction. The newly emerged JN.1 dominated the globally circulating variants in a short time and resulted in increasing hospitalizations. Up to 2024, variant vaccines with the composition of XBB sub-lineage were available due to the coordinated efforts of developers and regulatory agencies. The development of updated vaccines is still needed and the regular availability of coronavirus disease 2019 (COVID-19) vaccines should be timely guaranteed. The current landscape of COVID-19 vaccines and the strategies for accelerating vaccine development and approval are reviewed. Proposals to enhance variants monitoring and the establishment of the strain recommendation mechanism are made. This review provides suggestions about platform technology designation and application, real-world data leveraging and modification to regulatory pathways both for the post-pandemic era of SARS-CoV-2 and for the future unknown pathogen pandemic.

References

1	WHO Director-General's Opening Remarks at the Media Briefing. May 5, 2023. World Health Organization. Updated May 5, 2023.
2	Tracking SARS-CoV-2 Variants. World Health Organization. Updated February 16, 2024.
3	C Willyard. Are repeat COVID infections dangerous? What the science says. Nature. 2023;616(7958):650-652.
4	E Callaway. COVID's future: mini-waves rather than seasonal surges. Nature. 2023;617(7960):229-230.
5	Moderna COVID-19 Vaccine (2023?2024 Formula) Authorized For Individuals 6 Months through 11 Years of Age. U.S. Food and Drug Administration. Updated November 1, 2023.
6	Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) Authorized For Individuals 6 Months through 11 Years of Age. U.S. Food and Drug Administration. Updated December 11, 2023.
7	Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) Authorized For Individuals 12 Years of Age and Older. U.S. Food and Drug Administration. Updated October 17, 2023.
8	New Drugs Approved in April 2023. PMDA.
9	X He, T Zhang, S Huan, Y Yang. Novel influenza vaccines: from research and development (R&D) challenges to regulatory responses. Vaccines (Basel). 2023;11(10):1573.
10	Vaccine Administration Law of the People's Republic of China. The National People's Congress of the People's Republic of China. December 29, 2021. Updated June 29, 2019.
11	Provisions for Drug Registration (2020 Issued, Order No. 27). Beijing, China: State Administration for Market Regulation; 2020.
12	Z Huang, Z Fu, J Wang. Review on drug regulatory science promoting COVID-19 vaccine development in China. Engineering (Beijing). 2022;10:127-132.
13	Emergency Use Listing Procedure. World Health Organization.
14	Drug Administration Law of the People's Republic of China. National Medical Products Administration (NMPA). 2019.
15	Vaccine Administration Law of the People's Republic of China. National Medical Products Administration (NMPA). 2019.
16	Provisions of Drug Registration. State Administration for Market Regulation. 2020.
17	Announcement of the National Medical Products Administration on the Release of Three Documents, including the “Breakthrough Therapy Drug Evaluation Procedure (Trial)” (No. 82 of 2020). National Medical Products Administration (NMPA). 2020.
18	Emergency Use Authorization for Vaccines to Prevent COVID-19. Center for Biologics Evaluation and Research. FDA.
19	Expedited Programs for Serious Conditions | Drugs and Biologics. Center for Drug Evaluation and Research. FDA.
20	On the Conditional Marketing Authorisation for Medicinal Products for Human Use Falling Within the Scope of Regulation (EC) No 726/2004 of the European Parliament and of the Council. 2006.
21	Guideline on the Scientific Application and the Practical Arrangements Necessary to Implement Regulation (EC) No 507/2006 on the Conditional Marketing Authorisation for Medicinal Products for Human Use Falling Within the Scope of Regulation (EC) No 726/2004. European Medicines Agency.
22	Guideline on the Scientific Application and the Practical Arrangements Necessary to Implement Regulation (EC) No 507/2006 on the Conditional Marketing Authorisation for Medicinal Products for Human Use Falling Within the Scope of Regulation (EC) No … European Medicines Agency.
23	Vaccine Development: Capabilities and Challenges for Addressing Infectious Diseases. United States Government Accountability Office. 2021.
24	H Zhang, L Zhang, A Lin, et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature. 2023;621(7978):396-403.
25	Recommendations for Inactivated Rabies Vaccine for Human Use Produced in Cell Substrates and Embryonated Eggs, Annex 2, TRS No. 941. World Health Organization. Updated January 1, 2007.
26	Recommendations for the Production and Control of Influenza Vaccine (Inactivated), Annex 3, TRS No. 927. World Health Organization. Updated January 1, 2005.
27	Recommendations to Assure the Quality, Safety and Efficacy of Recombinant Hepatitis B Vaccines, Annex 4, TRS No. 978. World Health Organization. Updated May 25, 2013.
28	DS Khoury, D Cromer, A Reynaldi, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-1211.
29	KA Earle, DM Ambrosino, A Fiore-Gartland, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423-4428.
30	T D?rner, A Radbruch. Antibodies and B cell memory in viral immunity. Immunity. 2007;27(3):384-392.
31	DJH Wyllie, R Mulchandani, A Trickey, et al. SARS-CoV-2 responsive T cell numbers and anti-Spike IgG levels are both associated with protection from COVID-19: a prospective cohort study in keyworkers. medRxiv. 2021.
32	AT Tan, M Linster, CW Tan, et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 2021;34(6):108728.
33	L Guan, Y Yu, X Wu, et al. The first Chinese national standards for SARS-CoV-2 neutralizing antibody. Vaccine. 2021;39(28):3724-3730.
34	WHO/BS.2020.2403 Establishment of the WHO International Standard and Reference Panel for Anti-SARS-CoV-2 Antibody. World Health Organization. Updated November 18, 2020.
35	Reflection Paper on the Regulatory Requirements for Vaccines Intended to Provide Protection Against Variant Strain(s) of SARS-CoV-2. European Medicines Agency: Science Medicines Health. Updated February 23, 2021.
36	Guidance on Strain Changes in Authorised COVID-19 Vaccines. GOV.UK. Updated March 4, 2021.
37	C He, A Alu, H Lei, et al. A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2. MedComm. 2023;4(3):e263.
38	Pfizer-Letter-of Authorization-(Reissued )for-2023-2024-Formula-final. U.S. Food and Drug Administration. Updated September 11, 2023.
39	La FDA Emprende Acciones con Respecto a las Vacunas Contra el COVID-19 de ARNm Actualizadas Para Mejorar la Protección Contra las Variantes que Circulan Actualmente. World Health Organization. Updated September 11, 2023.
40	Coronavirus (COVID-19) Update: FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines. World Health Organization. Updated April 18, 2023.
41	K Bollaerts, C Wyndham-Thomas, E Miller, et al. The role of real-world evidence for regulatory and public health decision-making for accelerated vaccine deployment—a meeting report. Biologicals. 2024;85:101750.
42	Statement on the Antigen Composition of COVID-19 Vaccines. World Health Organization. Updated April 26, 2024.
43	Vaccines Eligible for WHO Prequalification. World Health Organization.